Stocks · News reference

HCW Biologics shares are trading higher after the company announced pricing of $1.5 million private placement.

Sep 24, 2026, 2:36 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARSep 24, 2026, 12:30 PMSEC EDGAR
8-K filing — HCW Biologics Inc. (HCWB)
Filed: 2026-09-24 AccNo: 0001493152-26-044078 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HCWB
BenzingaSep 24, 2026, 12:28 PMBenzinga Newsdesk
HCW Biologics Prices $1.5M Private Placement Of 903,614 Units At $1.6599 Per Unit
Company agreed to issue and sell an aggregate of 903,614 units (the "Units"), with each Unit consisting of (i) one pre-funded warrant (a "Pre-Funded Warrant") to purchase one share of the Company’s
HCWB
Globenewswire IncSep 8, 2026, 12:50 PMNa
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.
HCWB